Literature DB >> 3963762

Topical therapy for oropharyngeal symptoms of myasthenia gravis.

J M Dooley, K J Goulden, J G Gatien, E J Gibson, B S Brown.   

Abstract

Inhibitors of acetylcholinesterase are commonly used in the treatment of myasthenia gravis. We studied a patient with mainly bulbar myasthenia gravis who did not tolerate oral pyridostigmine despite a clear clinical response. Treatment with nebulized pyridostigmine reduced her symptoms without systemic side effects. This route of therapy may benefit other patients.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3963762     DOI： 10.1002/ana.410190214

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  4 in total

Review 1.  Juvenile myasthenia: diagnosis and treatment.

Authors:  B Anlar
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

2.  Efficacy of intranasal administration of neostigmine in myasthenic patients.

Authors:  A Sghirlanzoni; D Pareyson; C Benvenuti; G Cei; V Cosi; M Lombardi; M Nicora; R Ricciardi; F Cornelio
Journal:  J Neurol       Date:  1992-03       Impact factor: 4.849

3.  Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation.

Authors:  R Ricciardi; B Rossi; M Nicora; A Sghirlanzoni; A Muratorio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-12       Impact factor: 10.154

4.  Reversal of experimental paralysis in a human by intranasal neostigmine aerosol suggests a novel approach to the early treatment of neurotoxic envenomation.

Authors:  Matthew R Lewin; Philip Bickler; Tom Heier; John Feiner; Lance Montauk; Brett Mensh
Journal:  Clin Case Rep       Date:  2013-07-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.